Addex Therapeutics Ltd. Sponsored ADR ADXN
3.65
0.19
5.49%
as of 25 Sep
- Market cap
- $3.6M
- P/E
- 0.0×
Follow ADXN
Growth Flags
show if company had growth for consecutive years
| Mar '26 | Dec '25 | Sep '25 | Jun '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | 0.00 | 0.00 | — |
+8 more quarters Free account |
P/S ratio |
— | 68.53 | 38.74 | — | |
P/FCF ratio |
— | 0.00 | 0.00 | — | |
P/Operating CF |
— | (10.13) | (12.61) | — | |
P/B ratio |
— | 1.20 | 1.19 | — | |
Price to Tangible BV |
— | 1.21 | 1.20 | — | |
EV/Sales |
— | 48.91 | 26.82 | — | |
EV/EBITDA |
— | 0.00 | 0.00 | — | |
EV/Operating CF |
— | (1.88) | (3.31) | — | |
EV/FCF |
— | (1.88) | (3.30) | — | |
Quick Ratio |
0.79 | 1.38 | 1.91 | 2.03 | |
Current Ratio |
0.97 | 1.40 | 2.01 | 2.31 | |
Net Debt/EBITDA |
1.99 | 2.06 | 3.15 | 3.15 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.01 | 0.02 | 0.00 | |
Operating CF/Net income |
0.45 | 0.30 | 0.36 | 0.25 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | (6,760.00%) | 769.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | (92,050.00%) | 1,742.86% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | (1,150.00%) | 55.26% | 0.00% | |
Graham Net Nets |
— | 0.01 | 0.14 | — | |
Graham Number |
— | 0.00 | 0.00 | — | |
Earnings Yield |
— | (120.76%) | (85.58%) | — | |
Free Cash Flow Yield |
— | (37.99%) | (20.99%) | — | |
Revenue per Share |
0.00 | 0.00 | 0.04 | 0.00 | |
Operating CF per Share |
(0.99) | (0.76) | (0.75) | (0.68) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.99) | (0.76) | (0.75) | (0.68) | |
Cash per Share |
1.21 | 2.21 | 2.91 | 3.33 | |
Shareholders Equity per Share |
4.25 | 6.43 | 7.93 | 10.43 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.25 | 6.43 | 7.93 | 10.43 | |
Free Cash Flow |
(0.98) | (0.68) | (0.70) | (0.57) | |
Working Capital |
(0.04) | 0.58 | 1.49 | 1.83 | |
Net Current Asset Value |
(0.36) | 0.10 | 1.24 | 1.65 | |
EV/EBIT |
— | 0.00 | 0.00 | — | |
Capex to Sales |
— | 0.00 | 0.00 | — | |
Net Profit Margin |
0.00% | 228,000.00% | (5,312.13%) | 0.00% | |
Price to Operating Income |
— | 0.00 | 0.00 | — | |
| Other line items | |||||
Average Receivables |
0.04 | 0.02 | 0.31 | 0.35 | |
Average Payables |
1.23 | 1.17 | 1.24 | 1.21 | |
Average Assets |
8.31 | 9.91 | 11.61 | 12.73 | |
Average Common Equity |
6.71 | 8.37 | 10.11 | 11.37 |
Columns are period end dates